[go: up one dir, main page]

BR112015012234A2 - Peptídios sema5b e vacinas contendo os mesmos - Google Patents

Peptídios sema5b e vacinas contendo os mesmos

Info

Publication number
BR112015012234A2
BR112015012234A2 BR112015012234A BR112015012234A BR112015012234A2 BR 112015012234 A2 BR112015012234 A2 BR 112015012234A2 BR 112015012234 A BR112015012234 A BR 112015012234A BR 112015012234 A BR112015012234 A BR 112015012234A BR 112015012234 A2 BR112015012234 A2 BR 112015012234A2
Authority
BR
Brazil
Prior art keywords
peptides
sema5b
methods
ctls
well
Prior art date
Application number
BR112015012234A
Other languages
English (en)
Inventor
Yoshimura Sachiko
Watanabe Tomohisa
Tsunoda Takuya
Osawa Ryuji
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BR112015012234A2 publication Critical patent/BR112015012234A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PEPTÍDIOS SEMA5B E VACINAS CONTENDO OS MESMOS. Vacinas peptídicas contra câncer são descritas na invenção. Em particular, peptídios epítopos isolados derivados do gene SEMA5B fazendo surgir CTLs e são desejáveis para uso no contexto da imunoterapia de câncer são oferecidos. Os peptídios inventivos abrangem tanto peptídios derivados de SEMA5B quanto versões modificadas destes, nas quais um, dois ou vários aminoácidos são substituídos, deletados, inseridos ou acrescentados, contanto que tais versões conservem a indutibilidade de CTL requisito das sequências originais. São oferecidos ainda polinucleotídeos codificando tais peptídios bem como composições farmacêuticas incluindo quaisquer desses peptídios ou polinucleotídeos como agentes ativos. Células apresentadoras de antígeno e CTLs isoladas que vetorizam tais peptídios, bem como métodos para induzir a célula apresentadra de antígeno, ou CTL também são oferecidos. Ademais, a invenção oferece métodos para tratamento e/ou profilaxia (isto é, prevenção) de cânceres (tumores), como câncer de esôfago, NSCLC, RCC e SCLC, e/ou prevenção de recorrência metastática ou pós-operatória destes, bem como métodos para induzir CTLs, métodos para induzir imunidade antitumoral, usando os peptídios derivados de SEMA5B, polinucleotídeos os codificando, ou células apresentadoras de antígeno apresentando-os, ou as composições farmacêuticas da invenção.
BR112015012234A 2012-12-04 2013-12-02 Peptídios sema5b e vacinas contendo os mesmos BR112015012234A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261733279P 2012-12-04 2012-12-04
PCT/JP2013/007051 WO2014087626A1 (en) 2012-12-04 2013-12-02 Sema5b peptides and vaccines containing the same

Publications (1)

Publication Number Publication Date
BR112015012234A2 true BR112015012234A2 (pt) 2017-08-15

Family

ID=50883068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012234A BR112015012234A2 (pt) 2012-12-04 2013-12-02 Peptídios sema5b e vacinas contendo os mesmos

Country Status (13)

Country Link
US (1) US20150322112A1 (pt)
JP (1) JP2016502499A (pt)
KR (1) KR20150091311A (pt)
CN (1) CN105814073A (pt)
AU (1) AU2013356143A1 (pt)
BR (1) BR112015012234A2 (pt)
CA (1) CA2892369A1 (pt)
IL (1) IL238788A0 (pt)
MX (1) MX2015007015A (pt)
RU (1) RU2015126849A (pt)
SG (1) SG11201503918XA (pt)
TW (1) TW201431874A (pt)
WO (1) WO2014087626A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6481873B2 (ja) * 2015-03-09 2019-03-13 日本電気株式会社 Ｍｕｃ１由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
GB201505585D0 (en) * 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109434A1 (en) * 2001-03-19 2003-06-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
US7514084B2 (en) * 2002-09-12 2009-04-07 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
DE10344799A1 (de) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102005013846A1 (de) * 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
JP2009502112A (ja) * 2005-07-28 2009-01-29 オンコセラピー・サイエンス株式会社 腎細胞癌を診断および処置するための方法
TWI434853B (zh) * 2007-04-11 2014-04-21 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
TW200932260A (en) * 2007-11-28 2009-08-01 Oncotherapy Science Inc STAT3 epitope peptides
TW201136604A (en) * 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
AU2011236397A1 (en) * 2010-04-09 2012-11-01 Oncotherapy Science, Inc. CDCA5 peptides and vaccines including the same
TW201302800A (zh) * 2011-06-10 2013-01-16 Oncotherapy Science Inc Ｓｅｍａ５ｂ胜肽及含其之疫苗

Also Published As

Publication number Publication date
MX2015007015A (es) 2015-09-28
US20150322112A1 (en) 2015-11-12
WO2014087626A1 (en) 2014-06-12
SG11201503918XA (en) 2015-06-29
RU2015126849A (ru) 2017-01-12
CA2892369A1 (en) 2014-06-12
KR20150091311A (ko) 2015-08-10
CN105814073A (zh) 2016-07-27
TW201431874A (zh) 2014-08-16
IL238788A0 (en) 2015-06-30
JP2016502499A (ja) 2016-01-28
AU2013356143A1 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
BR112015021828A2 (pt) Peptídeos de kntc2 e vacinas que contêm os mesmos
MX2010014044A (es) Peptidos de epitope cdca1 y vacunas que contienen los mismos.
BR112015004349A2 (pt) peptídeos de ube2t e vacinas contendo os mesmos
MX380003B (es) Péptidos topk y vacunas que incluyen los mismos.
MX350220B (es) Peptidos de mphosph1 y vacunas que incluyen los mismos.
MX2013014489A (es) Peptidos sema5b y vacunas que incluyen los mismos.
EP4219525A3 (en) Foxm1-derived peptide, and vaccine including same
BR112015012234A2 (pt) Peptídios sema5b e vacinas contendo os mesmos
EP4353321A3 (en) Koc1-derived peptide and vaccine including same
BR112013005448A2 (pt) peptídeos de ttll4 e vacinas contendo os mesmos.
BR112012022641A2 (pt) peptídeos hjurp e vacinas que incluem os mesmos
MX342000B (es) Peptidos ect2 y vacunas que los incluyen.
MX2011010191A (es) Peptidos c6orf167 y vacunas que continen los mismos.
EP3848383A3 (en) Urlc10-derived peptide and vaccine containing same
SG10201900879PA (en) Cdca1-derived peptide and vaccine containing same
MX2012011666A (es) Peptidos cluap1 y vacunas que incluyen los mismos.
PH12012501935A1 (en) Ect2 peptides and vaccines including the same
MY194241A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC
MY194244A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc
MY194653A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY193910A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
EA202090822A2 (ru) Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл
MX2019013161A (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2433 DE 22-08-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]